Top

Published in:

Open Access 15-03-2023 | Positron Emission Tomography | Gastrointestinal

Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma

Authors: Jonathan L. Moore, Manil Subesinghe, Aida Santaolalla, Michael Green, Harriet Deere, Mieke Van Hemelrijck, Jesper Lagergren, Sugama Chicklore, Nick Maisey, James A. Gossage, Mark Kelly, Cara R. Baker, Andrew R. Davies, On behalf of the Guy’s and St Thomas’ Oesophago-gastric Research Group

Published in: European Radiology | Issue 5/2023

Abstract

Objectives

2-deoxy-2[¹⁸F]Fluoro-d-glucose (FDG) PET-CT has an emerging role in assessing response to neoadjuvant therapy in oesophageal cancer. This study evaluated FDG PET-CT in predicting pathological tumour response (pTR), pathological nodal response (pNR) and survival.

Methods

Cohort study of 75 patients with oesophageal or oesophago-gastric junction (GOJ) adenocarcinoma treated with neoadjuvant chemotherapy then surgery at Guy’s and St Thomas’ NHS Foundation Trust, London (2017–2020). Standardised uptake value (SUV) metrics on pre- and post-treatment FDG PET-CT in the primary tumour (mTR) and loco-regional lymph nodes (mNR) were derived. Optimum SUV_max thresholds for predicting pathological response were identified using receiver operating characteristic analysis. Predictive accuracy was compared to PERCIST (30% SUV_max reduction) and MUNICON (35%) criteria. Survival was assessed using Cox regression.

Results

Optimum tumour SUV_max decrease for predicting pTR was 51.2%. A 50% cut-off predicted pTR with 73.5% sensitivity, 69.2% specificity and greater accuracy than PERCIST or MUNICON (area under the curve [AUC] 0.714, PERCIST 0.631, MUNICON 0.659). Using a 30% SUV_max threshold, mNR predicted pNR with high sensitivity but low specificity (AUC 0.749, sensitivity 92.6%, specificity 57.1%, p = 0.010). pTR, mTR, pNR and mNR were independent predictive factors for survival (pTR hazard ratio [HR] 0.10 95% confidence interval [CI] 0.03–0.34; mTR HR 0.17 95% CI 0.06–0.48; pNR HR 0.17 95% CI 0.06–0.54; mNR HR 0.13 95% CI 0.02–0.66).

Conclusions

Metabolic tumour and nodal response predicted pTR and pNR, respectively, in patients with oesophageal or GOJ adenocarcinoma. However, currently utilised response criteria may not be optimal. pTR, mTR, pNR and mNR were independent predictors of survival.

Key Points

• FDG PET-CT has an emerging role in evaluating response to neoadjuvant therapy in patients with oesophageal cancer.

• Prospective cohort study demonstrated that metabolic response in the primary tumour and lymph nodes was predictive of pathological response in a cohort of patients with adenocarcinoma of the oesophagus or oesophago-gastric junction treated with neoadjuvant chemotherapy followed by surgical resection.

• Patients who demonstrated a response to neoadjuvant chemotherapy in the primary tumour or lymph nodes on FDG PET-CT demonstrated better survival and reduced rates of tumour recurrence.

Available only for authorised users

Miyata H, Yamasaki M, Makino T et al (2016) Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. Br J Surg 103(1):97–104. https://doi.org/10.1002/BJS.9965CrossRefPubMed

Findlay JM, Gillies RS, Franklin JM et al (2016) Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. Eur Radiol 26(10):3519–3533. https://doi.org/10.1007/S00330-016-4227-4CrossRefPubMed

Findlay JM, Bradley KM, Wang LM et al (2017) Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. Br J Surg 104(4):408–417. https://doi.org/10.1002/bjs.10611CrossRefPubMed

Foley K, Findlay J, Goh V (2018) Novel imaging techniques in staging oesophageal cancer. Best Pract Res Clin Gastroenterol 36–37:17–25. https://doi.org/10.1016/j.bpg.2018.11.009CrossRefPubMed

Findlay JM, Bradley KM et al (2017) Predicting pathologic response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalized therapy. J Nucl Med 58(2):266–275. https://doi.org/10.2967/JNUMED.116.176313CrossRefPubMed

Davies AR, Myoteri D, Zylstra J et al (2018) Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. Br J Surg 105(12):1639–1649. https://doi.org/10.1002/bjs.10900CrossRefPubMed

Evans RP, Kamarajah SK, Kunene V, et al. Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma. Eur J Surg Oncol. 2022;0(0). https://doi.org/10.1016/J.EJSO.2021.12.021

Noorani A, Li X, Goddard M, Crawte J et al (2020) Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat Genet 52(1):74. https://doi.org/10.1038/S41588-019-0551-3CrossRefPubMedPubMedCentral

Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9):797–805. https://doi.org/10.1016/S1470-2045(07)70244-9CrossRefPubMed

10.

Wahl RL, Jacene H, Kasamon Y et al (2009) Response criteria in solid tumors. J Nucl Med 50(Suppl 1):122–150. https://doi.org/10.2967/jnumed.108.057307CrossRef

11.

Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058–3065. https://doi.org/10.1200/JCO.2001.19.12.3058CrossRefPubMed

12.

Union for International Cancer Control (UICC). TNM classification of malignant tumours - eighth edition. J B, editor. Wiley Blackwell

13.

Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification , pathology and extent of resection Tumor Type Adeno Ca of the Distal Esophagus True Ca Cardia Anatomical. 1996;173–82

14.

Mandard FJ , Dalibard JC, Mandard J, et al. 1994 Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer.73(11)

15.

Textor J, Van Der Zander B, Gilthorpe MS, et al. Software application profile robust causal inference using directed acyclic graphs: the R package “dagitty”; https://doi.org/10.1093/ije/dyw341

16.

Downey RJ, Akhurst T, Ilson D et al (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21(3):428–432. https://doi.org/10.1200/JCO.2003.04.013CrossRefPubMed

17.

Kim MK, Ryu JS, Kim SB et al (2007) Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43(9):1385–1391. https://doi.org/10.1016/J.EJCA.2007.04.001CrossRefPubMed

18.

Gillies RS, Middleton MR, Blesing C et al (2012) Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. Eur Radiol 22(9):2035–2043. https://doi.org/10.1007/S00330-012-2459-5CrossRefPubMed

19.

Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692–4698. https://doi.org/10.1200/JCO.2006.06.7801CrossRefPubMed

20.

Goodman KA, Ou FS, Hall NC et al (2021) Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 39(25):2803–2815. https://doi.org/10.1200/JCO.20.03611CrossRefPubMedPubMedCentral

Title: Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
Authors: Jonathan L. Moore
Manil Subesinghe
Aida Santaolalla
Michael Green
Harriet Deere
Mieke Van Hemelrijck
Jesper Lagergren
Sugama Chicklore
Nick Maisey
James A. Gossage
Mark Kelly
Cara R. Baker
Andrew R. Davies
On behalf of the Guy’s and St Thomas’ Oesophago-gastric Research Group
Publication date: 15-03-2023
Publisher: Springer Berlin Heidelberg
Keywords: Positron Emission Tomography
Cytostatic Therapy
Published in: European Radiology / Issue 5/2023
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-023-09482-7

At a glance: The STEP trials

Springer Medicine

Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma

Abstract

Objectives

Methods

Results

Conclusions

Key Points

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 5/2023

Accuracy and reproducibility of a cone beam CT-based virtual parenchymal perfusion algorithm in the prediction of SPECT/CT anatomical and volumetric results during the planification of radioembolization for HCC

Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas

Intranodal dynamic contrast-enhanced CT lymphangiography and dynamic contrast-enhanced MR lymphangiography in microminipig

Grading meningiomas with diffusion metrics: a comparison between diffusion kurtosis, mean apparent propagator, neurite orientation dispersion and density, and diffusion tensor imaging

Contrast-enhanced CT radiomics improves the prediction of abdominal aortic aneurysm progression

Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients